1. Home
  2. PRU vs A Comparison

PRU vs A Comparison

Compare PRU & A Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRU
  • A
  • Stock Information
  • Founded
  • PRU 1875
  • A 1999
  • Country
  • PRU United States
  • A United States
  • Employees
  • PRU N/A
  • A N/A
  • Industry
  • PRU Life Insurance
  • A Biotechnology: Laboratory Analytical Instruments
  • Sector
  • PRU Finance
  • A Industrials
  • Exchange
  • PRU Nasdaq
  • A Nasdaq
  • Market Cap
  • PRU N/A
  • A 29.3B
  • IPO Year
  • PRU N/A
  • A 1999
  • Fundamental
  • Price
  • PRU $109.08
  • A $121.38
  • Analyst Decision
  • PRU Hold
  • A Buy
  • Analyst Count
  • PRU 13
  • A 13
  • Target Price
  • PRU $120.15
  • A $139.67
  • AVG Volume (30 Days)
  • PRU 1.5M
  • A 1.8M
  • Earning Date
  • PRU 07-30-2025
  • A 08-20-2025
  • Dividend Yield
  • PRU 4.95%
  • A 0.82%
  • EPS Growth
  • PRU 7.49
  • A N/A
  • EPS
  • PRU 6.33
  • A 4.06
  • Revenue
  • PRU $60,366,000,000.00
  • A $6,628,000,000.00
  • Revenue This Year
  • PRU N/A
  • A $6.13
  • Revenue Next Year
  • PRU $5.05
  • A $5.64
  • P/E Ratio
  • PRU $17.23
  • A $29.89
  • Revenue Growth
  • PRU N/A
  • A 0.56
  • 52 Week Low
  • PRU $90.38
  • A $96.43
  • 52 Week High
  • PRU $130.55
  • A $153.84
  • Technical
  • Relative Strength Index (RSI)
  • PRU 63.14
  • A 63.54
  • Support Level
  • PRU $105.22
  • A $116.84
  • Resistance Level
  • PRU $109.68
  • A $123.16
  • Average True Range (ATR)
  • PRU 1.71
  • A 2.56
  • MACD
  • PRU 0.44
  • A 0.18
  • Stochastic Oscillator
  • PRU 87.55
  • A 81.18

About A Agilent Technologies Inc.

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.

Share on Social Networks: